PTC THERAPEUTICS, INC. cotiza a 64.70 USD y tiene una capitalización bursátil de $5.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.92 | $-0.03 | $-1.80 |
| Estimado | $0.30 | $0.34 | $-0.44 | $-0.40 |
| Sorpresa | — | +170.6% | +93.2% | -350.0% |
| Métrica | PTCT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 50.1% | -38.6% | +88.7% |
| Net Margin | 39.4% | -33.6% | +73.0% |
| FCF Margin | 40.6% | -13.9% | +54.4% |
| ROE | — | -40.4% | — |
| ROA | 23.6% | -32.0% | +55.6% |
| Current Ratio | 2.35 | 2.84 | -0.49 |
| Debt / Equity | — | 0.28 | — |